Cargando…

Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway

BACKGROUND: Recent studies suggest that there is a potential connection between obstructive sleep apnea (OSA) and osteoporosis through dysregulation of bone metabolism. Orexin-A, a neuroprotective peptide secreted by the hypothalamus, is at a lower level in the plasma of OSA patients, which regulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Hong, Ru, Yiwen, Wang, Wei, Cai, Guanhui, Gu, Lanxin, Ye, Junjie, Zhang, Wei-Bing, Wang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270907/
https://www.ncbi.nlm.nih.gov/pubmed/35818538
http://dx.doi.org/10.2147/DDDT.S363286
_version_ 1784744568445468672
author Gu, Hong
Ru, Yiwen
Wang, Wei
Cai, Guanhui
Gu, Lanxin
Ye, Junjie
Zhang, Wei-Bing
Wang, Lin
author_facet Gu, Hong
Ru, Yiwen
Wang, Wei
Cai, Guanhui
Gu, Lanxin
Ye, Junjie
Zhang, Wei-Bing
Wang, Lin
author_sort Gu, Hong
collection PubMed
description BACKGROUND: Recent studies suggest that there is a potential connection between obstructive sleep apnea (OSA) and osteoporosis through dysregulation of bone metabolism. Orexin-A, a neuroprotective peptide secreted by the hypothalamus, is at a lower level in the plasma of OSA patients, which regulates appetite, energy expenditure and sleep-wake states. However, the protective effect of orexin-A on bone metabolism in OSA is unclear. PURPOSE: To investigate whether the activation of OX1R by orexin-A can reverse bone mass loss induced by chronic intermittent hypoxia (CIH). METHODS: Mice were randomly divided into the normoxia group and CIH group. Within the CIH or normoxia groups, treatment groups were given a subcutaneous injection of either orexin-A or saline vehicle once every day for 4 weeks and then femurs were removed for micro-CT scans. Histology and immunohistochemical staining were performed to observe and calculate the changes in femurs as a result of hypoxia. Cell immunofluorescence and immunohistochemical staining were used to detect the expression of orexin receptors in MC3T3-E1 cells or in bones. CCK-8 assay, ALP assay kit and alizarin red staining were used to detect the viability, alkaline phosphatase (ALP) activity, and capacity of mineralization, respectively. The effect of orexin-A on osteogenic differentiation of MC3T3-E1 cells was evaluated using qRT-PCR, Western blot and cell staining. RESULTS: CIH led to a decrease in the amount and density of trabecular bone, downregulated OCN expression while increasing osteoclast numbers in femurs and inhibited the expression of RUNX2, OSX, OPN and Nrf2 in MC3T3-E1 cells. Orexin-A treatment alleviated these CIH-induced effects by combining to OX1R. The level of HIF-1α was elevated both in CIH and orexin-A treatment groups. CONCLUSION: CIH environment inhibits osteogenesis and orexin-A can reverse bone mass loss induced by CIH through OX1R-Nrf2/HIF-1α pathway.
format Online
Article
Text
id pubmed-9270907
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92709072022-07-10 Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway Gu, Hong Ru, Yiwen Wang, Wei Cai, Guanhui Gu, Lanxin Ye, Junjie Zhang, Wei-Bing Wang, Lin Drug Des Devel Ther Original Research BACKGROUND: Recent studies suggest that there is a potential connection between obstructive sleep apnea (OSA) and osteoporosis through dysregulation of bone metabolism. Orexin-A, a neuroprotective peptide secreted by the hypothalamus, is at a lower level in the plasma of OSA patients, which regulates appetite, energy expenditure and sleep-wake states. However, the protective effect of orexin-A on bone metabolism in OSA is unclear. PURPOSE: To investigate whether the activation of OX1R by orexin-A can reverse bone mass loss induced by chronic intermittent hypoxia (CIH). METHODS: Mice were randomly divided into the normoxia group and CIH group. Within the CIH or normoxia groups, treatment groups were given a subcutaneous injection of either orexin-A or saline vehicle once every day for 4 weeks and then femurs were removed for micro-CT scans. Histology and immunohistochemical staining were performed to observe and calculate the changes in femurs as a result of hypoxia. Cell immunofluorescence and immunohistochemical staining were used to detect the expression of orexin receptors in MC3T3-E1 cells or in bones. CCK-8 assay, ALP assay kit and alizarin red staining were used to detect the viability, alkaline phosphatase (ALP) activity, and capacity of mineralization, respectively. The effect of orexin-A on osteogenic differentiation of MC3T3-E1 cells was evaluated using qRT-PCR, Western blot and cell staining. RESULTS: CIH led to a decrease in the amount and density of trabecular bone, downregulated OCN expression while increasing osteoclast numbers in femurs and inhibited the expression of RUNX2, OSX, OPN and Nrf2 in MC3T3-E1 cells. Orexin-A treatment alleviated these CIH-induced effects by combining to OX1R. The level of HIF-1α was elevated both in CIH and orexin-A treatment groups. CONCLUSION: CIH environment inhibits osteogenesis and orexin-A can reverse bone mass loss induced by CIH through OX1R-Nrf2/HIF-1α pathway. Dove 2022-07-05 /pmc/articles/PMC9270907/ /pubmed/35818538 http://dx.doi.org/10.2147/DDDT.S363286 Text en © 2022 Gu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gu, Hong
Ru, Yiwen
Wang, Wei
Cai, Guanhui
Gu, Lanxin
Ye, Junjie
Zhang, Wei-Bing
Wang, Lin
Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
title Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
title_full Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
title_fullStr Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
title_full_unstemmed Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
title_short Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
title_sort orexin-a reverse bone mass loss induced by chronic intermittent hypoxia through ox1r-nrf2/hif-1α pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270907/
https://www.ncbi.nlm.nih.gov/pubmed/35818538
http://dx.doi.org/10.2147/DDDT.S363286
work_keys_str_mv AT guhong orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT ruyiwen orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT wangwei orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT caiguanhui orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT gulanxin orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT yejunjie orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT zhangweibing orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway
AT wanglin orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway